Sort   by:  
 Page size 
ProteomicsComprehensive investigation of (redox-) proteomic changes induced by cana-, dapa-, empagliflozin treatment in cardiac cells
One of the major macrovascular complications that can occur in type 2 diabetes is the development of cardiovascular diseases as for instance heart failure. However, sodium-glucose co-transporter-2 (SGLT-2) inhibitors have shortly after their approval shown to decrease death rates in diabetic patient...
ORGANISM(S): Homo sapiens (Human) 
2026-01-20 | PXD063467 | Pride
Gliflozins Sglt-2 inhibitors Proteomics Ac16 cells Heart failure Oxidative stress Hcm cells Empagliflozin Redox proteomics Canagliflozin Dapagliflozin 
UnknownDiscovery of a New Antibiotic Demethoxytetronasin Using a Dual-Sided Agar Plate Assay (DAPA).
Not available
S-EPMC10426401 | biostudies-literature
UnknownIron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF.
Not available
S-EPMC9508991 | biostudies-literature
ProteomicsCardioprotection by selective SGLT2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect?
Major clinical trials with sodium glucose co-transporter-2 inhibitors (SGLT-2i) exhibit protective effects against heart failure events, whereas inconsistencies regarding the cardiovascular death outcomes are observed. Therefore, we aimed to compare the selective SGLT-2i empagliflozin (EMPA), dapagl...
ORGANISM(S): Mus Musculus (ncbitaxon:10090) 
2021-12-17 | MSV000088582 | MassIVE
UnknownCharacterization of the dapA-nlpB genetic locus involved in regulation of swarming motility, cell envelope architecture, hemolysin production, and cell attachment ability in Serratia marcescens.
Not available
S-EPMC1231142 | biostudies-literature
UnknownExtrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis.
Not available
S-EPMC10157747 | biostudies-literature
UnknownDapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial.
Not available
S-EPMC10883141 | biostudies-literature
UnknownEffect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy.
Not available
S-EPMC7809714 | biostudies-literature
UnknownClinical Outcomes and Healthcare Resource Utilization in a Real-World Population Reflecting the DAPA-CKD Trial Participants.
Not available
S-EPMC7889671 | biostudies-literature
UnknownProjecting the benefit of vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA trial.
Not available
S-EPMC11911596 | biostudies-literature
Sort   by:  
 Page size